Document 0433
 DOCN  M9440433
 TI    Prevalence of antibody to hepatitis C virus (HCV) in HIV-1-infected
       patients (nice SEROCO cohort).
 DT    9404
 AU    Quaranta JF; Delaney SR; Alleman S; Cassuto JP; Dellamonica P; Allain
       JP; Service de Medecine Interne II, Hematologie, Hopital de; Cimiez, CHU
       Nice, France.
 SO    J Med Virol. 1994 Jan;42(1):29-32. Unique Identifier : AIDSLINE
       MED/94141475
 AB    The prevalence of antibody to hepatitis C virus (HCV) in a cohort of 272
       HIV-infected patients was assessed by means of 4 anti-HCV assays: a 1st
       generation and a neutralization test, a 2nd generation test, and a
       confirmatory test, the dot-blot Matrix HCV immunoassay. The cohort
       included, as a single risk factor, 35.7% intravenous drug users (IVDUs),
       25% homosexual men, 30.1% heterosexual individuals, 5.9% transfused
       patients, 0.7% occupational infections, and 2.6% patients with unknown
       infection source, and was studied on entry and in samples collected for
       up to 36 months. Results showed that on entry (i) sera of 83 out of 272
       members of the cohort were positive by the HCV 1st generation EIA
       (30.5%); 70 were confirmed by the neutralization test (84.3%); (ii) 115
       of the cohort were reactive with the 2nd generation HCV EIA (41.3%);
       (iii) with the dot-blot immunoassay 99 (86.1%) of the cohort were
       confirmed and 16 remained indeterminate. The overall confirmed HCV
       antibody-positive rate in these 272 patients was 36.4%. Antibody to HCV
       was detected in 78.3% of IVDUs, 18.3% of heterosexual individuals, 31.2%
       of transfused patients, and only 2.9% of homosexual men. The 36-month
       follow-up of this cohort revealed that 4/145 patients became anti-HCV
       positive by second generation assay. Hepatitis B markers were frequently
       associated with HCV in IVDUs (71.1%) but infrequently in heterosexual
       (8.5%) or homosexual (1.5%) individuals. Our results suggest that HCV
       2nd generation EIA used in combination with the semiautomated dot-blot
       assay as a confirmatory test improves the specificity and sensitivity
       for HCV antibody detection.(ABSTRACT TRUNCATED AT 250 WORDS)
 DE    Adolescence  Adult  Aged  Biological Markers  Blood Transfusion  Cohort
       Studies  Comparative Study  Enzyme-Linked Immunosorbent Assay  Female
       France/EPIDEMIOLOGY  Hepatitis Antibodies/*BLOOD  Hepatitis
       B/COMPLICATIONS  Hepatitis C/COMPLICATIONS/*EPIDEMIOLOGY/IMMUNOLOGY
       Hepatitis C Viruses/*IMMUNOLOGY  Homosexuality  Human  HIV
       Infections/*COMPLICATIONS/IMMUNOLOGY  *HIV-1  Immunoblotting  Male
       Middle Age  Recombinant Proteins  Substance Abuse, Intravenous  Viral
       Nonstructural Proteins  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).